A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy, safety, and tolerability of JNJ-27018966 in the treatment of patients with diarrhea-predominant irritable bowel syndrome,
Role: Investigator,
Furiex Pharmaceuticals,
(07/2012 - 07/2013)
Status: Completed
Prospective observational study on predictors of early on-treatment response and sustained virological response in a cohort of treatment naive HCV-infected patients treated with pegylated interferons,
Role: Investigator,
Hoffmann-La Roche Inc.,
(11/2010 - 11/2011)
Status: Completed
Multicenter, randomized, open-labeled, controlled study of the effect of treatment with once weekly Pegasys® plus daily Copegus® with or without concomitant pioglitazone (Actos®) on early viral kinetics in treatment-naive patients with chronic hepatitis C (genotype-1 HCV infection) and insulin resistance,
Role: Investigator,
Hoffmann-La Roche Inc.,
(08/2010 - 08/2011)
Status: Completed
A multicenter, open-labeled study of the long-term safety and efficacy of lubiprostone in patients with opioid-induced bowel dysfunction,
Role: PI,
Sucampo Pharmaceuticals, Inc.,
(09/2009 - 09/2010)
Status: Completed
A randomized double-blind parallel study of rabeprazole extended-release 50 mg versus esomeprazole 40 mg for healing and symptomatic relief of moderate to severe erosive gastroesophageal reflux disease (GERD),
Role: PI,
Eisai Medical Research, Inc.,
(02/2009 - 02/2010)
Status: Completed
A multicenter, randomized, placebo-controlled, doubleblinded study of the efficacy and safety of lubiprostone in patients with opioid-induced bowel dysfuction,
Role: PI,
Sucampo Pharmaceuticals, Inc.,
(01/2009 - 01/2010)
Status: Completed
Internal
Percutaneous jejunostomy feeding tubes: A case series in pregnant patients,
Role: PI,
LLU Dept. of Gastroenterology,
(03/2009 - 03/2010)
Status: Completed
Expected rate of decline of liver enzymes after a successful ERCP for obstructive jaundice,
Role: PI,
LLU Dept. of Medicine,
(01/2008 - 01/2009)
Status: Completed
Chlorhexidine versus povidone-iodine as cutaneous antisepsis for prevention of PEG site infection - a pilot study,
Role: PI,
LLU Dept. of Medicine,
(08/2007 - 08/2008)
Status: Completed